Tag: Anti-CD20 Monoclonal Antibodies (Mabs) Market Analysis

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Anti-CD20 Monoclonal Antibodies Market Poised To Hit $12.94 Billion By 2030 With A 7.5% CAGR

The anti-cd20 monoclonal antibodies market size has observed strong growth in recent years. It is projected to expand from $9 billion in 2025 to $9.7 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.8%. The historical growth of the market can be linked to the approval and extensive use of rituximab, the increasing prevalence of non-hodgkin’s lymphoma and chronic lymphocytic leukemia, heightened awareness of targeted therapies, the presence of hospital pharmacy distribution channels, and the wider adoption of intravenous administration routes.

The market size for anti-cd20 monoclonal antibodies is set to experience significant expansion in the coming years. It is projected to achieve a value of $12.94 billion by 2030, with a compound annual growth rate (CAGR) of 7.5%. This growth over the forecast period is fueled by the introduction of obinutuzumab and ofatumumab biosimilars, the wider acceptance of subcutaneous formulations, increased investment in research and academic institutions, the expansion of ambulatory care facilities, and the rising need for anti-cd20 treatments in various autoimmune diseases. Prominent trends for the forecast duration include the increasing use of monoclonal antibody therapies for b-cell malignancies, the ongoing development of biosimilars and next-generation anti-cd20 antibodies, the broader availability of subcutaneous and patient-friendly administration methods, a heightened focus on personalized and targeted immunotherapy, and an uptick in clinical trials and research in both autoimmune and oncology fields.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25693&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Anti-CD20 Monoclonal Antibodies Market Expansion Drivers: What’s Shaping Future Growth?

An anticipated increase in autoimmune diseases is projected to drive the expansion of the anti-CD20 monoclonal antibodies market. These conditions manifest when the body’s immune system mistakenly targets its own cells as harmful, initiating an attack. The rise in autoimmune diseases is linked to increased exposure to environmental pollutants, which can disrupt immune regulation and provoke assaults on bodily tissues. Anti-CD20 monoclonal antibodies offer a treatment for autoimmune diseases by eradicating B cells, which are involved in generating autoantibodies and inflammation, thereby assisting in modulating immune responses and alleviating disease symptoms. Illustratively, Arthritis Australia, a non-profit organization based in Australia, reported in February 2024 that approximately 562,378 Australians are anticipated to have RA in 2025, constituting 14% of all arthritis cases for that year. Projections indicate a 33% increase by 2040, reaching 748,721 people, which signifies an additional 186,343 Australians living with RA in 2040 compared to 2025. Consequently, the increasing prevalence of autoimmune diseases is stimulating the growth of the anti-CD20 monoclonal antibodies market.

Anti-CD20 Monoclonal Antibodies Market Segments: Where Is Growth Concentrated?

The anti-cd20 monoclonal antibodies market covered in this report is segmented –

1) By Product Type: Rituximab, Obinutuzumab, Ofatumumab, Other Product Types

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (Cll), Rheumatoid Arthritis, Multiple Sclerosis, Pemphigus Vulgaris, Other Applications

5) By End-User: Hospitals, Surgical Centers and Diagnostic Centers, Maternity Centers, Ambulatory Care Centers, Research And Academia, Other End-Users

Subsegments:

1) By Rituximab: Rituxan, Truxima, Ruxience, Reditux

2) By Obinutuzumab: Gazyva, Biosimilar Candidates

3) By Ofatumumab: Arzerra, Kesimpta

4) By Other Product Types: Ublituximab, Veltuzumab, Ocrelizumab, Mosunetuzumab

Anti-CD20 Monoclonal Antibodies Market Strategic Trends: What Defines The Next Growth Phase?

Leading companies within the anti-CD20 monoclonal antibody market are concentrating on creating sophisticated products, including obinutuzumab, to more efficiently combat resistant or recurrent B-cell malignancies. This product, obinutuzumab, functions as a humanized type II anti-CD20 monoclonal antibody, engineered to locate and eliminate CD20-positive B cells implicated in specific blood cancers and autoimmune conditions. An example of this progress is from March 2025, when Roche, a biopharmaceutical firm headquartered in Switzerland, disclosed that the US Food and Drug Administration (FDA) had granted acceptance to a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) intended for the management of lupus nephritis. This acceptance stems from favorable outcomes observed in the Phase III REGENCY study, which demonstrated an enhanced complete renal response (CRR) when administered alongside standard therapy, compared to standard therapy by itself. Consequently, Gazyva/Gazyvaro stands as the sole anti-CD20 monoclonal antibody to exhibit this particular advantage in treating lupus nephritis, a serious inflammatory condition resulting from lupus that can culminate in kidney failure.

Anti-CD20 Monoclonal Antibodies Market Key Participants And Competitive Landscape

Major companies operating in the anti-cd20 monoclonal antibodies market are F. Hoffmann-La Roche Ltd., Novartis AG, Biogen Idec, TG Therapeutics, Celltrion Inc., Shanghai Henlius Biotech Inc., Innovent Biologics, Dr. Reddy’s Laboratories Ltd., Genmab A/S, AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Sanofi SA, Bristol-Myers Squibb Company, Samsung Bioepis, Sandoz International GmbH, Amneal Pharmaceuticals LLC, Viatris Inc., Intas Pharmaceuticals Ltd., Lupin Limited, Zydus Lifesciences Ltd., Aurobindo Pharma Ltd., Biocon Biologics Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Hetero Biopharma Ltd., Reliance Life Sciences Pvt. Ltd., Adello Biologics, Mabion SA, mAbxience, Probiomed S.A. de C.V., Prestige Biopharma Ltd., CinnaGen Co., JHL Biotech Inc., Amgen Biologics Pvt. Ltd.

View The Full Anti-CD20 Monoclonal Antibodies Market Report:

https://www.thebusinessresearchcompany.com/report/anti-cd20-monoclonal-antibodies-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Anti-CD20 Monoclonal Antibodies Market Global Footprint: Which Region Leads The Market?

North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-cd20 monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Anti-CD20 Monoclonal Antibodies Market Forecast: What Market Value Is Expected By 2030?

The market for anti-CD20 monoclonal antibodies has experienced robust expansion over recent years. Projections indicate it will rise from $9 billion in 2025 to $9.7 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. This historic growth has been driven by several factors, including the approval and extensive adoption of rituximab, an increasing prevalence of non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, heightened recognition of targeted therapeutic approaches, the accessibility of hospital pharmacy distribution networks, and a broadening range of intravenous administration pathways.

The market for anti-cd20 monoclonal antibodies is anticipated to demonstrate significant growth over the next several years, reaching $12.94 billion by 2030 at a compound annual growth rate of 7.5%. This forecasted expansion is driven by the emergence of obinutuzumab and ofatumumab biosimilars, broader adoption of subcutaneous formulations, increased research and academic funding, the growth of ambulatory care centers, and rising demand for anti-cd20 therapies across multiple autoimmune conditions. During the forecast period, major trends will include greater use of monoclonal antibody treatments for B-cell malignancies, the creation of biosimilars and next-generation anti-cd20 antibodies, expanded subcutaneous and patient-friendly administration methods, a heightened emphasis on personalized and targeted immunotherapy, and an upsurge in clinical trials and research activities in both autoimmune and oncology indications.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25693&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Anti-CD20 Monoclonal Antibodies Market Expansion Supported By Key Demand Factors

The anticipated increase in autoimmune conditions is set to drive forward the anti-CD20 monoclonal antibodies market. These disorders arise when the immune system mistakenly targets the body’s own cells as foreign and mounts an assault against them. Their prevalence is climbing due to heightened exposure to environmental contaminants, which can disrupt immune regulation and provoke attacks on bodily tissues. Anti-CD20 monoclonal antibodies address autoimmune diseases by removing B cells responsible for generating autoantibodies and triggering inflammation. This therapy aids in modulating immune responses and alleviating disease manifestations. As an example, in February 2024, Arthritis Australia, a non-profit entity based in Australia, reported that an estimated 562,378 Australians will be affected by rheumatoid arthritis (RA) in 2025, representing 14% of all arthritis cases that year. By 2040, this figure is projected to surge by 33% to 748,721 individuals, marking an increase of 186,343 Australians living with RA relative to 2025. Consequently, the rising incidence of autoimmune diseases is fueling expansion in the anti-CD20 monoclonal antibodies market.

Anti-CD20 Monoclonal Antibodies Market Segment Landscape: Which Areas Lead Market Development?

The anti-cd20 monoclonal antibodies market covered in this report is segmented –

1) By Product Type: Rituximab, Obinutuzumab, Ofatumumab, Other Product Types

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (Cll), Rheumatoid Arthritis, Multiple Sclerosis, Pemphigus Vulgaris, Other Applications

5) By End-User: Hospitals, Surgical Centers and Diagnostic Centers, Maternity Centers, Ambulatory Care Centers, Research And Academia, Other End-Users

Subsegments:

1) By Rituximab: Rituxan, Truxima, Ruxience, Reditux

2) By Obinutuzumab: Gazyva, Biosimilar Candidates

3) By Ofatumumab: Arzerra, Kesimpta

4) By Other Product Types: Ublituximab, Veltuzumab, Ocrelizumab, Mosunetuzumab

Anti-CD20 Monoclonal Antibodies Market Growth Trends Influencing Competitive Dynamics

Key players within the anti-CD20 monoclonal antibody sector are concentrating on creating next-generation therapies like obinutuzumab to better address resistant or recurrent B-cell malignancies. Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, is engineered to identify and eliminate CD20-positive B cells that are involved in specific blood cancers and autoimmune conditions. As an illustration, in March 2025, Roche—a biopharmaceutical firm headquartered in Switzerland—revealed that the US Food and Drug Administration (FDA) had accepted a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) aimed at treating lupus nephritis. This decision is based on favorable findings from the Phase III REGENCY study, where obinutuzumab combined with conventional therapy resulted in a higher complete renal response (CRR) compared to conventional therapy alone. This development positions Gazyva/Gazyvaro as the only anti-CD20 monoclonal antibody to show this kind of advantage in lupus nephritis, a serious kidney inflammation brought on by lupus that may progress to kidney failure.

Anti-CD20 Monoclonal Antibodies Market Industry Leaders And Market Competition

Major companies operating in the anti-cd20 monoclonal antibodies market are F. Hoffmann-La Roche Ltd., Novartis AG, Biogen Idec, TG Therapeutics, Celltrion Inc., Shanghai Henlius Biotech Inc., Innovent Biologics, Dr. Reddy’s Laboratories Ltd., Genmab A/S, AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Sanofi SA, Bristol-Myers Squibb Company, Samsung Bioepis, Sandoz International GmbH, Amneal Pharmaceuticals LLC, Viatris Inc., Intas Pharmaceuticals Ltd., Lupin Limited, Zydus Lifesciences Ltd., Aurobindo Pharma Ltd., Biocon Biologics Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Hetero Biopharma Ltd., Reliance Life Sciences Pvt. Ltd., Adello Biologics, Mabion SA, mAbxience, Probiomed S.A. de C.V., Prestige Biopharma Ltd., CinnaGen Co., JHL Biotech Inc., Amgen Biologics Pvt. Ltd.

Access The Complete Anti-CD20 Monoclonal Antibodies Market Report:

https://www.thebusinessresearchcompany.com/report/anti-cd20-monoclonal-antibodies-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Anti-CD20 Monoclonal Antibodies Market Regional Outlook: Where Are The Largest Opportunities Located?

North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-cd20 monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Anti-CD20 Monoclonal Antibodies Market Between 2026 And 2030?

The anti-cd20 monoclonal antibodies market size has shown significant expansion in recent years. This market is anticipated to increase from $9 billion in 2025 to $9.7 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. The historical growth can be attributed to several factors, including the approval and extensive use of rituximab, the increasing incidence of non-hodgkin’s lymphoma and chronic lymphocytic leukemia, a growing understanding of targeted therapies, the presence of hospital pharmacy distribution channels, and the development of intravenous administration routes.

The anti-cd20 monoclonal antibodies market is expected to demonstrate significant expansion in the coming years, reaching $12.94 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.5%. This growth during the forecast period is attributed to several factors, including the development of obinutuzumab and ofatumumab biosimilars, an increase in the adoption of subcutaneous formulations, rising investment in research and academia, the expansion of ambulatory care centers, and a growing demand for anti-cd20 therapies in various autoimmune diseases. Prominent trends for this period include the increasing uptake of monoclonal antibody therapies for B-cell malignancies, the development of biosimilars and advanced anti-cd20 antibodies, the proliferation of subcutaneous and patient-friendly administration routes, a heightened focus on personalized and targeted immunotherapy, and a surge in clinical trials and research across autoimmune and oncology indications.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25693&type=smp

Which Factors Are Influencing The Growth Of The Anti-CD20 Monoclonal Antibodies Market?

The increasing incidence of autoimmune conditions is anticipated to drive expansion in the anti-CD20 monoclonal antibodies market. These conditions arise when the immune system mistakenly targets the body’s own cells, perceiving them as harmful and initiating an assault. A rise in autoimmune diseases is linked to increased exposure to environmental contaminants, which can disrupt immune system regulation and provoke attacks on bodily tissues. Anti-CD20 monoclonal antibodies address autoimmune diseases by eradicating B cells, which are responsible for generating autoantibodies and causing inflammation. Their function is to modulate the immune response and alleviate symptoms associated with these diseases. As an illustration, data from Arthritis Australia, a non-profit organization located in Australia, indicated in February 2024 that approximately 562,378 Australians are projected to have RA in 2025, making up 14% of all arthritis diagnoses for that year. This figure is forecast to climb by 33% to reach 748,721 individuals by 2040, signifying an increase of 186,343 Australians affected by RA in 2040 compared to 2025. Consequently, the escalating prevalence of autoimmune diseases is fueling the expansion of the anti-CD20 monoclonal antibodies market.

How Are Segments Identified Within The Anti-CD20 Monoclonal Antibodies Market Segment Framework?

The anti-cd20 monoclonal antibodies market covered in this report is segmented –

1) By Product Type: Rituximab, Obinutuzumab, Ofatumumab, Other Product Types

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (Cll), Rheumatoid Arthritis, Multiple Sclerosis, Pemphigus Vulgaris, Other Applications

5) By End-User: Hospitals, Surgical Centers and Diagnostic Centers, Maternity Centers, Ambulatory Care Centers, Research And Academia, Other End-Users

Subsegments:

1) By Rituximab: Rituxan, Truxima, Ruxience, Reditux

2) By Obinutuzumab: Gazyva, Biosimilar Candidates

3) By Ofatumumab: Arzerra, Kesimpta

4) By Other Product Types: Ublituximab, Veltuzumab, Ocrelizumab, Mosunetuzumab

Which Trends Are Shaping Growth In The Anti-CD20 Monoclonal Antibodies Market?

Major companies operating in the anti-CD20 monoclonal antibody market are concentrating on developing advanced products such as obinutuzumab to target resistant or relapsed B-cell malignancies more effectively. Obinutuzumab is a humanized type II anti-CD20 monoclonal antibody engineered to specifically target and eliminate CD20-positive B cells involved in certain blood cancers and autoimmune diseases. For instance, in March 2025, Roche, a Switzerland-based biopharmaceutical company, announced that the US Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) for the treatment of lupus nephritis. This decision is based on positive results from the Phase III REGENCY study, which showed an improved complete renal response (CRR) when combined with standard therapy compared to standard therapy alone. This positions Gazyva/Gazyvaro as the only anti-CD20 monoclonal antibody to demonstrate such benefit in lupus nephritis, a severe inflammation caused by lupus that can lead to kidney failure.

Who Are The Companies Competing Within The Anti-CD20 Monoclonal Antibodies Market?

Major companies operating in the anti-cd20 monoclonal antibodies market are F. Hoffmann-La Roche Ltd., Novartis AG, Biogen Idec, TG Therapeutics, Celltrion Inc., Shanghai Henlius Biotech Inc., Innovent Biologics, Dr. Reddy’s Laboratories Ltd., Genmab A/S, AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Sanofi SA, Bristol-Myers Squibb Company, Samsung Bioepis, Sandoz International GmbH, Amneal Pharmaceuticals LLC, Viatris Inc., Intas Pharmaceuticals Ltd., Lupin Limited, Zydus Lifesciences Ltd., Aurobindo Pharma Ltd., Biocon Biologics Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Hetero Biopharma Ltd., Reliance Life Sciences Pvt. Ltd., Adello Biologics, Mabion SA, mAbxience, Probiomed S.A. de C.V., Prestige Biopharma Ltd., CinnaGen Co., JHL Biotech Inc., Amgen Biologics Pvt. Ltd.

Get The Full Anti-CD20 Monoclonal Antibodies Market Report:

https://www.thebusinessresearchcompany.com/report/anti-cd20-monoclonal-antibodies-global-market-report

Which Region Holds The Highest Market Share In The Anti-CD20 Monoclonal Antibodies Market?

North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-cd20 monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Anti-CD20 Monoclonal Antibodies Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/anti-cd20-monoclonal-antibodies-global-market-report

Browse Through More Reports Similar to the Global Anti-CD20 Monoclonal Antibodies Market 2026, By The Business Research Company

Monoclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Monoclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Polyclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Anti-CD20 Monoclonal Antibodies Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The anti-cd20 monoclonal antibodies market size has observed significant growth in recent years. This market is forecast to expand from $9 billion in 2025 to $9.7 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. The historical expansion can be attributed to the approval and widespread adoption of rituximab, an increase in the incidence of non-hodgkin’s lymphoma and chronic lymphocytic leukemia, growing awareness of targeted therapies, the availability of hospital pharmacy distribution channels, and the broader use of intravenous administration routes.

The anti-cd20 monoclonal antibodies market size is projected to experience significant expansion over the coming years. It is anticipated to reach $12.94 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.5%. This growth during the forecast period is propelled by factors such as the development of obinutuzumab and ofatumumab biosimilars, the increasing acceptance of subcutaneous formulations, growing investment in research and academia, the expansion of ambulatory care centers, and an escalating demand for anti-cd20 therapies in numerous autoimmune diseases. Furthermore, key trends in the forecast period encompass a rising adoption of monoclonal antibody therapies for b-cell malignancies, the development of biosimilars and next-generation anti-cd20 antibodies, the expansion of subcutaneous and patient-friendly administration routes, an increasing focus on personalized and targeted immunotherapy, and the growing number of clinical trials and research efforts in autoimmune and oncology indications.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25693&type=smp

What Drivers Are Influencing The Anti-CD20 Monoclonal Antibodies Market?

The anticipated expansion of the anti-CD20 monoclonal antibodies market is linked to the increasing prevalence of autoimmune conditions. These conditions arise when the body’s immune system mistakenly attacks its own cells, perceiving them as harmful. A rise in environmental pollutant exposure, capable of disrupting immune regulation and initiating attacks on bodily tissues, contributes to the increase in autoimmune diseases. Anti-CD20 monoclonal antibodies address autoimmune disorders by eradicating B cells, which are responsible for producing autoantibodies and inflammation. These antibodies aid in modulating the immune system’s response and alleviating disease manifestations. For example, data from February 2024 by Arthritis Australia, an Australian non-profit, projects that approximately 562,378 Australians will have RA in 2025, representing 14% of all arthritis cases during that year. This figure is projected to climb by 33% to 748,721 people by 2040. This indicates an additional 186,343 Australians will be affected by RA in 2040 relative to 2025. Consequently, the increasing incidence of autoimmune conditions is a key driver for the expansion of the anti-CD20 monoclonal antibodies market.

What Major Segment Divisions Exist Within The Anti-CD20 Monoclonal Antibodies Market?

The anti-cd20 monoclonal antibodies market covered in this report is segmented –

1) By Product Type: Rituximab, Obinutuzumab, Ofatumumab, Other Product Types

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (Cll), Rheumatoid Arthritis, Multiple Sclerosis, Pemphigus Vulgaris, Other Applications

5) By End-User: Hospitals, Surgical Centers and Diagnostic Centers, Maternity Centers, Ambulatory Care Centers, Research And Academia, Other End-Users

Subsegments:

1) By Rituximab: Rituxan, Truxima, Ruxience, Reditux

2) By Obinutuzumab: Gazyva, Biosimilar Candidates

3) By Ofatumumab: Arzerra, Kesimpta

4) By Other Product Types: Ublituximab, Veltuzumab, Ocrelizumab, Mosunetuzumab

How Are Trends Shaping The Direction Of The Anti-CD20 Monoclonal Antibodies Market?

Leading entities within the anti-CD20 monoclonal antibody market are concentrating on creating enhanced products, including obinutuzumab, to more efficiently combat resistant or relapsed B-cell malignancies. This drug, obinutuzumab, functions as a humanized type II anti-CD20 monoclonal antibody, formulated to pinpoint and eliminate CD20-positive B cells linked to specific blood cancers and autoimmune conditions. An example of this advancement occurred in March 2025, when Roche, a biopharmaceutical firm based in Switzerland, disclosed that the US Food and Drug Administration (FDA) approved a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) for treating lupus nephritis. This acceptance was underpinned by favorable outcomes from the Phase III REGENCY study, which indicated an enhanced complete renal response (CRR) when the drug was used alongside standard therapy, compared to standard therapy by itself. Consequently, Gazyva/Gazyvaro stands as the sole anti-CD20 monoclonal antibody proven to offer such an advantage in lupus nephritis, a severe lupus-induced inflammation capable of resulting in kidney failure.

Which Companies Are Leading Innovation In The Anti-CD20 Monoclonal Antibodies Market?

Major companies operating in the anti-cd20 monoclonal antibodies market are F. Hoffmann-La Roche Ltd., Novartis AG, Biogen Idec, TG Therapeutics, Celltrion Inc., Shanghai Henlius Biotech Inc., Innovent Biologics, Dr. Reddy’s Laboratories Ltd., Genmab A/S, AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Sanofi SA, Bristol-Myers Squibb Company, Samsung Bioepis, Sandoz International GmbH, Amneal Pharmaceuticals LLC, Viatris Inc., Intas Pharmaceuticals Ltd., Lupin Limited, Zydus Lifesciences Ltd., Aurobindo Pharma Ltd., Biocon Biologics Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Hetero Biopharma Ltd., Reliance Life Sciences Pvt. Ltd., Adello Biologics, Mabion SA, mAbxience, Probiomed S.A. de C.V., Prestige Biopharma Ltd., CinnaGen Co., JHL Biotech Inc., Amgen Biologics Pvt. Ltd.

Read the full anti-cd20 monoclonal antibodies market report here:

https://www.thebusinessresearchcompany.com/report/anti-cd20-monoclonal-antibodies-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Anti-CD20 Monoclonal Antibodies Market?

North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-cd20 monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Anti-CD20 Monoclonal Antibodies Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25693&type=smp

Browse Through More Reports Similar to the Global Anti-CD20 Monoclonal Antibodies Market 2026, By The Business Research Company

Monoclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Monoclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Polyclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the anti-cd20 monoclonal antibodies market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Anti-CD20 Monoclonal Antibodies Market expected to grow between 2026 and 2030?

The anti-cd20 monoclonal antibodies market size has shown significant growth in recent years. It is anticipated to increase from $9 billion in 2025 to $9.7 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. This historical expansion can be attributed to the approval and widespread utilization of rituximab, a rising prevalence of non-hodgkin’s lymphoma and chronic lymphocytic leukemia, increasing recognition of targeted therapies, the presence of hospital pharmacy distribution channels, and the broadening of intravenous administration routes.

The anti-cd20 monoclonal antibodies market is anticipated to show robust growth in the coming years. This market is set to reach $12.94 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.5%. Factors contributing to this growth during the forecast period include the introduction of obinutuzumab and ofatumumab biosimilars, wider uptake of subcutaneous formulations, rising investment in research and academic fields, the proliferation of ambulatory care centers, and a surging demand for anti-cd20 treatments across various autoimmune conditions. Key trends anticipated for the forecast period encompass an escalating use of monoclonal antibody therapies for B-cell malignancies, the creation of biosimilars and advanced anti-cd20 antibodies, the proliferation of subcutaneous and more patient-convenient administration methods, a heightened emphasis on individualized and targeted immunotherapy, and an increase in clinical trials and research within autoimmune and oncology areas.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25693&type=smp

Which Drivers Are Influencing Market Acceleration In The Anti-CD20 Monoclonal Antibodies Market?

An anticipated increase in autoimmune diseases is projected to drive the expansion of the anti-CD20 monoclonal antibodies market in the future. These conditions arise when the body’s immune system mistakenly perceives its own cells as harmful and initiates an assault. The rise in autoimmune disorders is attributed to increased exposure to environmental pollutants, which can compromise immune system control and provoke attacks on bodily tissues. Anti-CD20 monoclonal antibodies address autoimmune diseases by eradicating B cells, which are responsible for generating autoantibodies and inflammation. These antibodies assist in regulating the immune response and alleviating disease manifestations. As an illustration, data from February 2024, provided by Arthritis Australia, an Australia-based non-profit entity, indicates that approximately 562,378 Australians are expected to have RA by 2025, constituting 14% of all arthritis cases for that year. This figure is projected to climb by 33% to 748,721 individuals by 2040. This signifies an additional 186,343 Australians living with RA in 2040 relative to 2025. Consequently, the increasing prevalence of autoimmune diseases is fueling the expansion of the anti-CD20 monoclonal antibodies market.

What Leading Segments Are Studied In The Anti-CD20 Monoclonal Antibodies Market?

The anti-cd20 monoclonal antibodies market covered in this report is segmented –

1) By Product Type: Rituximab, Obinutuzumab, Ofatumumab, Other Product Types

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (Cll), Rheumatoid Arthritis, Multiple Sclerosis, Pemphigus Vulgaris, Other Applications

5) By End-User: Hospitals, Surgical Centers and Diagnostic Centers, Maternity Centers, Ambulatory Care Centers, Research And Academia, Other End-Users

Subsegments:

1) By Rituximab: Rituxan, Truxima, Ruxience, Reditux

2) By Obinutuzumab: Gazyva, Biosimilar Candidates

3) By Ofatumumab: Arzerra, Kesimpta

4) By Other Product Types: Ublituximab, Veltuzumab, Ocrelizumab, Mosunetuzumab

What Upcoming Trends Are Likely To Define The Future Path Of The Anti-CD20 Monoclonal Antibodies Market?

Companies within the anti-CD20 monoclonal antibody market are prioritizing the creation of advanced products like obinutuzumab to address resistant or relapsed B-cell malignancies with greater efficacy. Obinutuzumab functions as a humanized type II anti-CD20 monoclonal antibody, engineered to specifically identify and eliminate CD20-positive B cells implicated in particular blood cancers and autoimmune conditions. For example, in March 2025, Roche, a Switzerland-based biopharmaceutical company, announced the US Food and Drug Administration (FDA)’s acceptance of a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) for its use in treating lupus nephritis. This acceptance is founded on favorable outcomes from the Phase III REGENCY study, which indicated an enhanced complete renal response (CRR) when administered alongside standard therapy compared to standard therapy alone. Consequently, Gazyva/Gazyvaro stands as the sole anti-CD20 monoclonal antibody to have demonstrated such a benefit in lupus nephritis, a severe inflammatory condition associated with lupus that can result in kidney failure.

Which Leading Companies Dominate The Anti-CD20 Monoclonal Antibodies Market Share?

Major companies operating in the anti-cd20 monoclonal antibodies market are F. Hoffmann-La Roche Ltd., Novartis AG, Biogen Idec, TG Therapeutics, Celltrion Inc., Shanghai Henlius Biotech Inc., Innovent Biologics, Dr. Reddy’s Laboratories Ltd., Genmab A/S, AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Sanofi SA, Bristol-Myers Squibb Company, Samsung Bioepis, Sandoz International GmbH, Amneal Pharmaceuticals LLC, Viatris Inc., Intas Pharmaceuticals Ltd., Lupin Limited, Zydus Lifesciences Ltd., Aurobindo Pharma Ltd., Biocon Biologics Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Hetero Biopharma Ltd., Reliance Life Sciences Pvt. Ltd., Adello Biologics, Mabion SA, mAbxience, Probiomed S.A. de C.V., Prestige Biopharma Ltd., CinnaGen Co., JHL Biotech Inc., Amgen Biologics Pvt. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/anti-cd20-monoclonal-antibodies-global-market-report

How Does The Anti-CD20 Monoclonal Antibodies Market Perform Across Major Global Regions?

North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-cd20 monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Anti-CD20 Monoclonal Antibodies Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25693&type=smp

Browse Through More Reports Similar to the Global Anti-CD20 Monoclonal Antibodies Market 2026, By The Business Research Company

Monoclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Monoclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Polyclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Anti-CD20 Monoclonal Antibodies Market Size Likely To Evolve From 2025 Through 2034?

The anti-CD20 monoclonal antibodies market size has demonstrated robust growth in recent years. This market is expected to expand from $8.33 billion in 2024 to $9.00 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.9%. Several factors contributed to its historical growth, including the increasing incidence of B-cell malignancies, broader use in autoimmune disease treatments, a rise in FDA and EMA approvals for new anti-CD20 therapies, and the globally expanding geriatric population.

The anti-CD20 monoclonal antibodies market is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $12.05 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.6%. This projected growth can be ascribed to several factors, including a rise in strategic collaborations and licensing agreements, broader application in combination therapies, a growing number of relapsed or refractory cases, increased healthcare spending and accessibility in developing regions, and accelerated development and approvals of biosimilars. Key trends identified for this period encompass progress in monoclonal antibody engineering, the incorporation of anti-CD20 antibodies into combination therapy regimens, technology-enabled customization of cancer treatments, innovations in subcutaneous and long-acting formulations, and breakthroughs in bispecific and next-generation antibodies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25693&type=smp

Which Industry Drivers Are Expected To Accelerate The Anti-CD20 Monoclonal Antibodies Market From 2025 To 2029?

The increasing incidence of autoimmune conditions is anticipated to drive the expansion of the anti-CD20 monoclonal antibodies market moving ahead. These diseases develop when the immune system mistakenly targets the body’s own cells as foreign invaders, initiating an attack. The prevalence of autoimmune disorders is on the rise, attributed to increased exposure to environmental contaminants that can disrupt immune system regulation and provoke assaults on bodily tissues. Anti-CD20 monoclonal antibodies address autoimmune conditions by eradicating B cells, which are responsible for producing autoantibodies and inflammation. They assist in moderating the immune response and alleviating the signs of the disease. For example, in June 2024, data from the Australian Institute of Health and Welfare, an Australia-based government organization, indicated that in 2022, approximately 514,000 individuals (2.0%) in Australia suffered from rheumatoid arthritis, a systemic autoimmune disorder, affecting 2.5% of females and 1.6% of males. Consequently, the expanding occurrence of autoimmune diseases is fueling the growth of the anti-CD20 monoclonal antibodies market.

What Are The Major Segments Identified In The Anti-CD20 Monoclonal Antibodies Market?

The anti-cd20 monoclonal antibodies market covered in this report is segmented –

1) By Product Type: Rituximab, Obinutuzumab, Ofatumumab, Other Product Types

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (Cll), Rheumatoid Arthritis, Multiple Sclerosis, Pemphigus Vulgaris, Other Applications

5) By End-User: Hospitals, Surgical Centers and Diagnostic Centers, Maternity Centers, Ambulatory Care Centers, Research And Academia, Other End-Users

Subsegments:

1) By Rituximab: Rituxan, Truxima, Ruxience, Reditux

2) By Obinutuzumab: Gazyva, Biosimilar Candidates

3) By Ofatumumab: Arzerra, Kesimpta

4) By Other Product Types: Ublituximab, Veltuzumab, Ocrelizumab, Mosunetuzumab

Which Competitive Trends Are Defining The Anti-CD20 Monoclonal Antibodies Market Structure?

Leading companies in the anti-CD20 monoclonal antibody market are prioritizing the development of advanced products, such as obinutuzumab, to more effectively target resistant or relapsed B-cell malignancies. Obinutuzumab is a humanized type II anti-CD20 monoclonal antibody specifically designed to identify and eliminate CD20-positive B cells involved in certain blood cancers and autoimmune diseases. For instance, in March 2025, Roche, a Switzerland-based biopharmaceutical company, announced that the US Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) for treating lupus nephritis. This decision follows positive data from the Phase III REGENCY study, which revealed an improved complete renal response (CRR) when combined with standard therapy compared to standard therapy alone. This positions Gazyva/Gazyvaro as the only anti-CD20 monoclonal antibody to show such a benefit in lupus nephritis, a severe inflammation caused by lupus that can result in kidney failure.

Which Major Industry Participants Are Leading The Anti-CD20 Monoclonal Antibodies Market Growth?

Major companies operating in the anti-cd20 monoclonal antibodies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Inc., Chugai Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories, Genmab A/S, Celltrion Inc., Innovent Biologics, Immunomedics, HLL Lifecare Limited, Shanghai Henlius Biotech Inc., TG Therapeutics, Biogen Idec, Aetos Pharma, Nycomed GmbH

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/anti-cd20-monoclonal-antibodies-global-market-report

How Do Regional Market Performances Compare Within The Anti-CD20 Monoclonal Antibodies Industry?

North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-cd20 monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Anti-CD20 Monoclonal Antibodies Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25693&type=smp

Browse Through More Reports Similar to the Global Anti-CD20 Monoclonal Antibodies Market 2025, By The Business Research Company

Monoclonal Antibodies Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Monoclonal Antibodies Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Polyclonal Antibodies Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Are The Market Size Estimates For The Anti-CD20 Monoclonal Antibodies Market?

The market size for anti-CD20 monoclonal antibodies has seen a substantial increase in the recent past. It is projected to inflate from $8.33 billion in 2024 to $9.00 billion come 2025, reflecting a compound annual growth rate (CAGR) of 7.9%. The surge during the historic period is linked to the increasing cases of B-cell malignancies, escalating use in the treatment of autoimmune diseases, a rise in FDA and EMA authorizations for newer anti-CD20 therapies, and a mounting global elderly population.

There is projected to be a significant expansion in the anti-CD20 monoclonal antibodies market over the coming years, reaching an estimated value of $12.05 billion in 2029, at a compound annual growth rate (CAGR) of 7.6%. The spur in growth during the prediction period could be due to increased strategic partnerships and licensing agreements, wider use in combination therapies, a growing occurrence of refractory or relapsed cases, rise in healthcare expenditure and access in burgeoning markets, and the acceleration in biosimilar development and approvals. Key trends for the forecast period include progress in monoclonal antibody engineering, the incorporation of anti-CD20 antibodies in combination treatments, customization of cancer therapies powered by technology, advances in subcutaneous and long-acting formulations and emergence of bispecific and next-generation antibodies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25693&type=smp

Which Industry Forces Are Driving The Anti-CD20 Monoclonal Antibodies Market Forward?

The increase in autoimmune diseases is anticipated to stimulate the expansion of the anti-CD20 monoclonal antibodies market. These diseases arise when the immune system incorrectly perceives the body’s cells as harmful and launches an assault on them. The rise in autoimmune diseases can be attributed to increasing exposure to environmental pollutants, which can negatively affect immune regulation and instigate attacks on the body’s tissues. Anti-CD20 monoclonal antibodies act as a treatment for such diseases by eradicating B cells that contribute to the production of autoantibodies and inflammation, thereby aiding in the regulation of the immune response and curtailing disease symptoms. For example, in June 2024, the Australian Institute of Health and Welfare, a government organization based in Australia, reported that in 2022, approximately 514,000 individuals (2.0%) in Australia were affected by rheumatoid arthritis, a systemic autoimmune disorder, with a prevalence rate of 2.5% among women and 1.6% among men. Consequently, the upsurge in autoimmune diseases is fueling the growth of the anti-CD20 monoclonal antibodies market.

How Is The Anti-CD20 Monoclonal Antibodies Market Organized By Different Segments?

The anti-cd20 monoclonal antibodies market covered in this report is segmented –

1) By Product Type: Rituximab, Obinutuzumab, Ofatumumab, Other Product Types

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (Cll), Rheumatoid Arthritis, Multiple Sclerosis, Pemphigus Vulgaris, Other Applications

5) By End-User: Hospitals, Surgical Centers and Diagnostic Centers, Maternity Centers, Ambulatory Care Centers, Research And Academia, Other End-Users

Subsegments:

1) By Rituximab: Rituxan, Truxima, Ruxience, Reditux

2) By Obinutuzumab: Gazyva, Biosimilar Candidates

3) By Ofatumumab: Arzerra, Kesimpta

4) By Other Product Types: Ublituximab, Veltuzumab, Ocrelizumab, Mosunetuzumab

What Current And Upcoming Trends Are Shaping The Anti-CD20 Monoclonal Antibodies Market?

Prominent businesses within the anti-CD20 monoclonal antibody market are prioritizing the creation of enhanced products such as obinutuzumab. This innovation specifically targets stubborn or recurring B-cell malignancies more effectively. Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, is designed to target and eradicate specific B cells involved in certain blood cancers and autoimmune diseases. For instance, Roche, a pharmaceutical company based in Switzerland, announced in March 2025 that a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) has been accepted by US Food and Drug Administration (FDA). This acceptance is based on positive results from the Phase III REGENCY study which showed improved complete renal response (CRR) when combined with standard therapy, outperforming standard therapy alone. This distinction establishes Gazyva/Gazyvaro as the solitary anti-CD20 monoclonal antibody showing such positive outcomes in the treatment of lupus nephritis, a severe inflammation triggered by lupus that could lead to kidney failure.

Who Are The Primary Market Leaders In The Anti-CD20 Monoclonal Antibodies Market?

Major companies operating in the anti-cd20 monoclonal antibodies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Inc., Chugai Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories, Genmab A/S, Celltrion Inc., Innovent Biologics, Immunomedics, HLL Lifecare Limited, Shanghai Henlius Biotech Inc., TG Therapeutics, Biogen Idec, Aetos Pharma, Nycomed GmbH

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/anti-cd20-monoclonal-antibodies-global-market-report

How Do Regional Dynamics Influence The Anti-CD20 Monoclonal Antibodies Market Performance?

North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-cd20 monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=25693&type=smp

Browse Through More Reports Similar to the Global Anti-CD20 Monoclonal Antibodies Market 2025, By The Business Research Company

Next Generation Antibody Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Anti Cancer Mabs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-cancer-mabs-global-market-report

Antibody Discovery Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antibody-discovery-global-market-report

About The Business Research Company:

With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Are The Market Size Estimates For The Anti-CD20 Monoclonal Antibodies Market?

The market size for anti-CD20 monoclonal antibodies has seen a substantial increase in the recent past. It is projected to inflate from $8.33 billion in 2024 to $9.00 billion come 2025, reflecting a compound annual growth rate (CAGR) of 7.9%. The surge during the historic period is linked to the increasing cases of B-cell malignancies, escalating use in the treatment of autoimmune diseases, a rise in FDA and EMA authorizations for newer anti-CD20 therapies, and a mounting global elderly population.

There is projected to be a significant expansion in the anti-CD20 monoclonal antibodies market over the coming years, reaching an estimated value of $12.05 billion in 2029, at a compound annual growth rate (CAGR) of 7.6%. The spur in growth during the prediction period could be due to increased strategic partnerships and licensing agreements, wider use in combination therapies, a growing occurrence of refractory or relapsed cases, rise in healthcare expenditure and access in burgeoning markets, and the acceleration in biosimilar development and approvals. Key trends for the forecast period include progress in monoclonal antibody engineering, the incorporation of anti-CD20 antibodies in combination treatments, customization of cancer therapies powered by technology, advances in subcutaneous and long-acting formulations and emergence of bispecific and next-generation antibodies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25693&type=smp

Which Industry Forces Are Driving The Anti-CD20 Monoclonal Antibodies Market Forward?

The increase in autoimmune diseases is anticipated to stimulate the expansion of the anti-CD20 monoclonal antibodies market. These diseases arise when the immune system incorrectly perceives the body’s cells as harmful and launches an assault on them. The rise in autoimmune diseases can be attributed to increasing exposure to environmental pollutants, which can negatively affect immune regulation and instigate attacks on the body’s tissues. Anti-CD20 monoclonal antibodies act as a treatment for such diseases by eradicating B cells that contribute to the production of autoantibodies and inflammation, thereby aiding in the regulation of the immune response and curtailing disease symptoms. For example, in June 2024, the Australian Institute of Health and Welfare, a government organization based in Australia, reported that in 2022, approximately 514,000 individuals (2.0%) in Australia were affected by rheumatoid arthritis, a systemic autoimmune disorder, with a prevalence rate of 2.5% among women and 1.6% among men. Consequently, the upsurge in autoimmune diseases is fueling the growth of the anti-CD20 monoclonal antibodies market.

How Is The Anti-CD20 Monoclonal Antibodies Market Organized By Different Segments?

The anti-cd20 monoclonal antibodies market covered in this report is segmented –

1) By Product Type: Rituximab, Obinutuzumab, Ofatumumab, Other Product Types

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (Cll), Rheumatoid Arthritis, Multiple Sclerosis, Pemphigus Vulgaris, Other Applications

5) By End-User: Hospitals, Surgical Centers and Diagnostic Centers, Maternity Centers, Ambulatory Care Centers, Research And Academia, Other End-Users

Subsegments:

1) By Rituximab: Rituxan, Truxima, Ruxience, Reditux

2) By Obinutuzumab: Gazyva, Biosimilar Candidates

3) By Ofatumumab: Arzerra, Kesimpta

4) By Other Product Types: Ublituximab, Veltuzumab, Ocrelizumab, Mosunetuzumab

What Current And Upcoming Trends Are Shaping The Anti-CD20 Monoclonal Antibodies Market?

Prominent businesses within the anti-CD20 monoclonal antibody market are prioritizing the creation of enhanced products such as obinutuzumab. This innovation specifically targets stubborn or recurring B-cell malignancies more effectively. Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, is designed to target and eradicate specific B cells involved in certain blood cancers and autoimmune diseases. For instance, Roche, a pharmaceutical company based in Switzerland, announced in March 2025 that a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) has been accepted by US Food and Drug Administration (FDA). This acceptance is based on positive results from the Phase III REGENCY study which showed improved complete renal response (CRR) when combined with standard therapy, outperforming standard therapy alone. This distinction establishes Gazyva/Gazyvaro as the solitary anti-CD20 monoclonal antibody showing such positive outcomes in the treatment of lupus nephritis, a severe inflammation triggered by lupus that could lead to kidney failure.

Who Are The Primary Market Leaders In The Anti-CD20 Monoclonal Antibodies Market?

Major companies operating in the anti-cd20 monoclonal antibodies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Inc., Chugai Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories, Genmab A/S, Celltrion Inc., Innovent Biologics, Immunomedics, HLL Lifecare Limited, Shanghai Henlius Biotech Inc., TG Therapeutics, Biogen Idec, Aetos Pharma, Nycomed GmbH

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/anti-cd20-monoclonal-antibodies-global-market-report

How Do Regional Dynamics Influence The Anti-CD20 Monoclonal Antibodies Market Performance?

North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-cd20 monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=25693&type=smp

Browse Through More Reports Similar to the Global Anti-CD20 Monoclonal Antibodies Market 2025, By The Business Research Company

Next Generation Antibody Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Anti Cancer Mabs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-cancer-mabs-global-market-report

Antibody Discovery Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antibody-discovery-global-market-report

About The Business Research Company:

With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Anti-CD20 Monoclonal Antibodies Sector?

In the past few years, the market size for anti-CD20 monoclonal antibodies has seen a robust expansion. It is anticipated to develop from $8.33 billion in 2024 to $9.00 billion in 2025, maintaining a compound annual growth rate (CAGR) of 7.9%. The surge in growth during the historical period can be associated with the escalating prevalence of B-cell malignancies, increased utilization in autoimmune disease remedies, a rise in FDA and EMA approvals for new anti-CD20 treatments, and an expanding elderly population worldwide.

The market for anti-CD20 monoclonal antibodies is projected to experience significant expansion in the coming years, reaching a value of $12.05 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.6%. The surge during this forecasted period can be ascribed to factors such as escalating strategic partnerships and licensing transactions, widening use in combination treatments, increasing instances of relapsed or unresponsive cases, growth in healthcare spending and access in emerging markets, and the rise in biosimilar creation and approvals. Key trends for this forecast period encompass progress in monoclonal antibody engineering, the incorporation of anti-CD20 antibodies into combination treatments, technological enhancements in personalizing cancer treatments, improvements in subcutaneous and long-acting formulations, as well as strides in bispecific and next-generation antibodies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25693&type=smp

What Forces Are Driving The Growth Of The Anti-CD20 Monoclonal Antibodies Market?

The surge in autoimmune diseases is anticipated to drive the expansion of the anti-CD20 monoclonal antibodies market in the future. When the body’s own cells are inaccurately targeted as threats by the immune system, such diseases occur. The rise in autoimmune diseases can be attributed to the increase in exposure to environmental pollutants which can damage immune regulation, leading to the body’s tissues being targeted. The treatment of autoimmune diseases involves the use of anti-CD20 monoclonal antibodies which eliminate B cells responsible for the production of autoantibodies and inflammation. They oversee the immune response and ease the symptoms of the disease. For example, the Australian Institute of Health and Welfare, a government organization based in Australia, reported in June 2024 that in 2022, approximately 514,000 individuals (2.0%) in Australia suffered from rheumatoid arthritis, a systemic autoimmune disorder. This affected 2.5% of females and 1.6% of males. Hence, the uptick in autoimmune diseases is fueling the growth of the anti-CD20 monoclonal antibodies market.

How Is The Anti-CD20 Monoclonal Antibodies Industry Segmented Across Key Parameters?

The anti-cd20 monoclonal antibodies market covered in this report is segmented –

1) By Product Type: Rituximab, Obinutuzumab, Ofatumumab, Other Product Types

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (Cll), Rheumatoid Arthritis, Multiple Sclerosis, Pemphigus Vulgaris, Other Applications

5) By End-User: Hospitals, Surgical Centers and Diagnostic Centers, Maternity Centers, Ambulatory Care Centers, Research And Academia, Other End-Users

Subsegments:

1) By Rituximab: Rituxan, Truxima, Ruxience, Reditux

2) By Obinutuzumab: Gazyva, Biosimilar Candidates

3) By Ofatumumab: Arzerra, Kesimpta

4) By Other Product Types: Ublituximab, Veltuzumab, Ocrelizumab, Mosunetuzumab

What Notable Trends Are Shaping The Direction Of The Anti-CD20 Monoclonal Antibodies Market?

Leading firms in the anti-CD20 monoclonal antibody sector are concentrating their efforts on the creation of sophisticated products such as obinutuzumab in order to more effectively tackle resistant or recurring B-cell malignancies. Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, is engineered to specifically target and eradicate CD20-positive B cells, which are implicated in certain blood cancers and autoimmune disorders. For example, in March 2025, Roche, a biopharmaceutical corporation based in Switzerland, disclosed that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to be used in the treatment of lupus nephritis. This action is driven by promising findings from the Phase III REGENCY clinical trial, which revealed a better complete renal response (CRR) when integrated with a regular treatment plan compared to a standard treatment alone. This achievement distinguishes Gazyva/Gazyvaro as the only anti-CD20 monoclonal antibody to display such an advantage in treating lupus nephritis, a severe inflammation triggered by lupus that can result in kidney failure.

Which Companies Currently Dominate The Competitive Landscape In The Anti-CD20 Monoclonal Antibodies Industry?

Major companies operating in the anti-cd20 monoclonal antibodies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Inc., Chugai Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories, Genmab A/S, Celltrion Inc., Innovent Biologics, Immunomedics, HLL Lifecare Limited, Shanghai Henlius Biotech Inc., TG Therapeutics, Biogen Idec, Aetos Pharma, Nycomed GmbH

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/anti-cd20-monoclonal-antibodies-global-market-report

Which Geographic Regions Are Driving Demand In The Anti-CD20 Monoclonal Antibodies Market?

North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-cd20 monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25693&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model